NeuShen Therapeutics is focused on advancing innovative therapies for psychiatric and neurological disorders through two primary platforms: NeuGem™ and NeuChime™. The NeuGem™ platform utilizes AAV (adeno-associated virus) gene therapy technology, which involves designing novel CNS-tropic AAV capsids and advanced gene expression cassettes. This approach aims to achieve efficient and safe gene therapies specifically targeting severe central nervous system (CNS) disorders. By employing world-class capsid engineering techniques, NeuShen seeks to enhance the delivery of therapeutic genes to the CNS, addressing complex pathologies associated with these diseases.

In addition to gene therapy, NeuShen's NeuChime™ platform is dedicated to small molecule drug discovery. This platform combines traditional drug discovery methods with cutting-edge AI-assisted technologies to create a diverse pipeline of novel treatments for psychiatric disorders, such as schizophrenia and depression. NeuShen aims to develop therapies that not only improve treatment outcomes but also offer faster onset and better long-term disease control with fewer side effects. The company is actively working on programs that are expected to enter IND (Investigational New Drug) enabling development soon, reflecting its commitment to addressing the unmet needs in the treatment of psychiatric conditions.

China

A global biotech company commited to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need.

We design novel CNS-tropic AAV capsids and innovative gene expression cassettes to achieve efficient, effective, and safe gene therapies for severe CNS disorders.

Central Nervous System (CNS)

Psychological Diseases

NeuShen Therapeutics

Central Nervous System Diseases

Neushen Therapeutics Drug #1

Biologics

Gene Therapy

Psychiatric disorder

Neushen Therapeutics Drug #2

Small Molecule Pharmaceuticals

Adeno-associated viral vector (AAV)

Antiviral Therapies

Artificial Intelligence

Therapeutic

NeuShen Therapeutics

Company Details